Pramlintide · Symlinpen, AC-0137

What is Pramlintide?

Pramlintide is a synthetic analog of human amylin, a hormone cosecreted with insulin by pancreatic beta cells. It slows gastric emptying, suppresses glucagon secretion, and increases satiety, thereby reducing postprandial glucose levels. It is used as adjunctive therapy in type 1 and type 2 diabetes patients on mealtime insulin who have not achieved adequate glycemic control.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Symlinpen, AC-0137, AC-137

Drug type

Peptide

Targets

amylin receptor

Mechanism

Agonist of amylin receptor

Pathways

gastric emptying, glucagon secretion, satiety, glucose homeostasis

Therapy area

Endocrine

Developer

Astrazeneca Ab

In trials of

XERS

FDA status

Approved as Symlinpen (March 16, 2005), NDA021332 · FDA label

UNII

D3FM8FA78T

✅ FDA-approved uses

• Type 1 diabetes as adjunctive treatment with mealtime insulin
• Type 2 diabetes as adjunctive treatment with mealtime insulin

From the indications section of the FDA label (version of Dec 18, 2019). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes Mellitus, Type 1Insulin-dependent Diabetes Mellitus

Sources

• FDA label (DailyMed)
• FDA label Symlinpen (2019-12-18), indications
• NCI Thesaurus

Updated Oct 3, 2026.